Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 9/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.41 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930913 | 0.90 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5EIF2AK1IDO1 | |
| SCHEMBL26047890 | 0.80 | CSF1R (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL10549450 | 0.79 | NPC1 (0.43) | FLT1 | |
| SCHEMBL23850846 | 0.79 | MAP2K1 (0.50) | MAP2K1MAP2K2FLT1IDO1 | |
| SCHEMBL31135631 | 0.79 | MAP2K1 (0.50) | MAP2K1MAP2K2FLT1IDO1 | |
| SCHEMBL12943607 | 0.78 | FLT1 (0.39) | MAP2K1MAP2K2FLT1MAP2K5EIF2AK1 | |
| SCHEMBL13747653 | 0.77 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL27883681 | 0.77 | EGFR (0.44) | MAP2K1MAP2K2 | |
| SCHEMBL31135613 | 0.76 | MAP2K1 (0.53) | MAP2K1MAP2K2FLT1IDO1 | |
| SCHEMBL23850839 | 0.76 | MAP2K1 (0.53) | MAP2K1MAP2K2FLT1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015392-A1 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | ASTRAZENECA AB | 2011-01-20 | — | — | US | disclosed |
| US-20110015392-A1 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | ASTRAZENECA AB | 2011-01-20 | — | — | US | disclosed |
| CN-101939298-A | Process for preparing pyridone derivatives | ASTRAZENECA AB | 2011-01-05 | — | — | CN | disclosed |
| EP-2252588-A2 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101432-A2 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009101432-A2 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015392-A1 | PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 | PDXK, MAPK1, PNPO | MAP2K1 172/4885MAP2K2 110/4885FLT1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.